by John R. Fischer
, Senior Reporter | April 06, 2018
MedyMatch Technology Ltd. will now go by the name MaxQ-AI, as a reflection of its initiative to bring AI-based clinical applications to market.
The Israeli-based enterprise made the announcement last month following the recent breakthrough designation awarded
by the FDA to its intracranial hemorrhage (ICH) detection application for stroke assessment and head trauma.
"Today we launch the MaxQ-AI brand to reflect a new day in the company's journey in bringing artificial intelligence-based clinical applications to the marketplace," Gene Saragnese, chairman and CEO of MaxQ-AI, said in a statement. "The health care industry is at an inflection point, at a ‘Max Q’ (a point of maximum pressure) – we believe AI has the potential to fundamentally reinvent health care as we know it, to deliver accurate and cost-effective patient care to billions of people around the world."
The ICH detection application, unveiled
in November 2016, can detect the presence of intracranial hemorrhages and brain bleeds in cases of head trauma and stroke; a difficult task but important, as there is a high risk of serious injury or death if they are misinterpreted or missed. It is designed as a second point of reference for physicians to use when making diagnoses.
This is just one in a series of applications that MaxQ-AI plans to develop alongside a variety of partners, one of which is Samsung Neurologica, which agreed
last March to integrate the ICH detection application into its 8-slice small-bore CereTom portable CT scanner.
MedyMatch also established another partnership in the same month with IBM Watson Health, which will distribute
the clinical decision support application through its vendor-neutral sales channels for integration into its other offerings, and which announced at RSNA this November its plans to integrate
its product with GE Healthcare CT systems.
“Many times a patient will come into the ER who bumped their head, have a headache or have some paralysis, and the question that has to be answered is whether they have blood in their brain,” Saragnese told HCB News at RSNA. “Our tool is designed to provide the second read or prioritize a case.”
MaxQ-AI did not respond for comment.